IL313177A - CCR8 antigen binding unit and its uses - Google Patents

CCR8 antigen binding unit and its uses

Info

Publication number
IL313177A
IL313177A IL313177A IL31317724A IL313177A IL 313177 A IL313177 A IL 313177A IL 313177 A IL313177 A IL 313177A IL 31317724 A IL31317724 A IL 31317724A IL 313177 A IL313177 A IL 313177A
Authority
IL
Israel
Prior art keywords
ccr8
antigen binding
binding unit
unit
antigen
Prior art date
Application number
IL313177A
Other languages
English (en)
Hebrew (he)
Inventor
David Bellovin
Min Chen
Xinchuan Dai
Lishan Kang
Shou Li
Hongshui Liu
Wenhua Shi
Bing Wan
Lina Wang
Shang Yin
Jing Zhang
Original Assignee
Zai Lab Shanghai Co Ltd
Zai Lab Us Llc
David Bellovin
Min Chen
Xinchuan Dai
Lishan Kang
Shou Li
Hongshui Liu
Wenhua Shi
Bing Wan
Lina Wang
Shang Yin
Jing Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zai Lab Shanghai Co Ltd, Zai Lab Us Llc, David Bellovin, Min Chen, Xinchuan Dai, Lishan Kang, Shou Li, Hongshui Liu, Wenhua Shi, Bing Wan, Lina Wang, Shang Yin, Jing Zhang filed Critical Zai Lab Shanghai Co Ltd
Publication of IL313177A publication Critical patent/IL313177A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL313177A 2021-12-02 2022-12-02 CCR8 antigen binding unit and its uses IL313177A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021134930 2021-12-02
PCT/CN2022/136276 WO2023098888A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Publications (1)

Publication Number Publication Date
IL313177A true IL313177A (en) 2024-07-01

Family

ID=86611552

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313177A IL313177A (en) 2021-12-02 2022-12-02 CCR8 antigen binding unit and its uses

Country Status (11)

Country Link
US (1) US20250034266A1 (https=)
EP (1) EP4441098A4 (https=)
JP (1) JP2024541680A (https=)
KR (1) KR20240112929A (https=)
CN (1) CN119072494A (https=)
AU (1) AU2022400921A1 (https=)
CA (1) CA3239784A1 (https=)
IL (1) IL313177A (https=)
MX (1) MX2024006743A (https=)
TW (1) TW202342533A (https=)
WO (1) WO2023098888A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4661869A1 (en) 2023-02-06 2025-12-17 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators
WO2024240224A1 (zh) * 2023-05-23 2024-11-28 再鼎医药(上海)有限公司 包含抗ccr8抗体的制剂及其用途
JPWO2024248037A1 (https=) 2023-05-30 2024-12-05
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN120230205A (zh) * 2023-12-29 2025-07-01 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
AU2022400921A1 (en) 2024-06-27
CA3239784A1 (en) 2023-06-08
KR20240112929A (ko) 2024-07-19
EP4441098A4 (en) 2026-03-04
JP2024541680A (ja) 2024-11-08
MX2024006743A (es) 2024-08-27
EP4441098A1 (en) 2024-10-09
TW202342533A (zh) 2023-11-01
WO2023098888A1 (en) 2023-06-08
US20250034266A1 (en) 2025-01-30
CN119072494A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
IL313177A (en) CCR8 antigen binding unit and its uses
IL283635A (en) Anti-cd3 binding molecules and their uses
EP4186926A4 (en) ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION
IL289102A (en) CD3 antigen-binding fragments and compositions comprising them
IL268258A (en) CD47 antigen binding unit and uses thereof
EP4025602A4 (en) TSLP BINDING ANTIBODIES AND USES THEREOF
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
ZA202210628B (en) Antibodies binding il4r and uses thereof
EP3847196A4 (en) BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
EP3733703A4 (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
IL304681A (en) psma binding proteins and uses thereof
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
EP3935183A4 (en) CD40-BINDING ANTIBODIES AND THEIR USES
EP4041772A4 (en) 4-1BB-BINDING ANTIBODIES AND USES THEREOF
IL280407A (en) IL-17A binding peptides and their medical uses
IL306082A (en) TROP2 binding antibodies and their uses
IL316176A (en) SIGLEC-8 binding proteins and their uses
IL304412A (en) Antibodies against cd112r and uses thereof
GB201909393D0 (en) Tau epitope and binding molecules
EP4286520A4 (en) Antigen-binding protein and use thereof
HK40117655A (en) Ccr8 antigen binding unit and uses thereof
IL308014A (en) Anti-galectin-9 antibodies and their therapeutic uses
EP4212551A4 (en) ANTIBODIES AGAINST HUMAN IL-5R AND USE THEREOF